1. Drug type: Bispecific antibody
2. Mechanism:It can synergistically block the inhibitory function of TIGIT and PD-L1 immune checkpoints and produce synergistic effects.
3. Research phase:Cell line was confirmed, and cell line stability study was completed. The pilot production and toxicology study is being started.
5. Research progress:
a)High yield cell lines have been obtained and cell line stability evaluation has been completed;
b)Efficacy study in vivo and in vitro of the asset have been confirmed;
c)High-yield monoclonal cell line has been determined, the upstream and downstream process routes have been cleared and verified;
d)The stability study of prescription has been completed, and will enter the pilot trial stage.
Emerging VoCs, Lambda, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ELISA kits for neutralizing antibody titer assay, binding antibody titer assay, antibody isotype assay, antigen titer assay and inhibitor screening, etc., which can accelerate the research and development of anti-SARS-CoV-2 drugs and vaccines.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.